HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.
A3161 Gemtuzumab (Anti-Siglec-3 / CD33) Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia.MW :145.22 KD.
A2650 Anti-TNFRSF21 / DR6 / CD358 Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD.
A2909 Anti-FGFR1 / CD331 Anti-FGFR1 / CD331 is a monoclonal antibody againts human fibroblast growth factor receptor 1. MW: 150 KD.
A2910 Anti-TSPAN8 Anti-TSPAN8 is a monoclonal IgG1 antibody (mAb) directed against Co-029, a membrane protein of the family of tetraspanins (TSPAN8 or TM4SF3). MW: 145.94 KD.
A2656 Anti-CSF3R / G-CSFR Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD.
A2914 Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD.
A2659 Anti-Haptoglobin Anti-Haptoglobin is an antibody targeting the human haptoglobin (HP). It can be used for immunoblotting after isoelectric focusing to determine Hp alpha subtypes. MW :150 KD.
A2915 Anti-ERG Anti-ERG is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer. MW: 145.4.
A2661 Ficlatuzumab (Anti-HGF / SF) Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
A2662 Emibetuzumab (Anti-HGFR / c-Met) Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.
A2663 Anti-IDO2 Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD.
A2665 Anrukinzumab (Anti-IL-13) Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.
A2666 Anti-IL-13Ra2 / CD213a2 Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD.
A2925 Anti-GPR64 / ADGRG2 Anti-GPR64 / ADGRG2 is a monoclonal antibody (mAb) against G protein-coupled receptor 64 isoform 4 (anti-GPR64) with potential anti-tumour activity. MW: 146.1.
A2672 Anti-MAGEA3 Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD.
A2929 Anti-KID3 Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD.
A2681 Brontictuzumab (Anti-NOTCH1) Brontictuzumab (Anti-NOTCH1) is a monoclonal antibody that targets Notch1 signal. It inhibits tumor cell proliferation and can be used in the research of leukemia and lymphoma. MW :150 KD.